GW-0742

GW-0742 is compelling as a concept; flip on one metabolic master switch and muscle starts behaving as if it has been training, leaning on fat for fuel, sparing glycogen, and building oxidative capacity. In rodents this translates into large endurance gains, less visceral fat, and better insulinthe hormone that moves sugar out of your blood and into cells sensitivity, which is why it anchors so much exercise-mimetic research.

The core mechanism is agonism of PPAR-beta/delta. Activating this nuclear receptor up-regulates the genes for fatty-acid oxidation and mitochondrialrelating to mitochondria, the cell's power plants fuel use, shifting substrate preference toward fat, and it drives mitochondrial biogenesis through the master regulator PGC-1alpha and related NRF-1 signaling ^[1][2]. GW-0742 also exerts anti-inflammatory effects by restraining the NF-kB pathway, suppressing inducible nitric oxidea gas that relaxes and widens blood vessels synthase and cytokines such as TNF-alpha, IL-1beta, and IL-6 across tissue-injury models ^[3].

The animal numbers are the eye-catching part. In trained mice, combining GW-0742 with the AMPKa cellular low-energy sensor that boosts efficiency and longevity pathways activator AICAR increased running time by roughly 138 to 179 percent relative to exercised controls and by about 355 percent relative to non-exercised controls, accompanied by a clear metabolic shift toward fat oxidation, elevated muscle non-esterified fatty acids, glycogen sparing, and up-regulation of Pgc1a, Pdk4, Cd36, and Lpl in muscle ^[1]. In diet-induced obese mice, GW-0742 complemented exercise to cut visceral adipose mass, improve insulinthe hormone that moves sugar out of your blood and into cells sensitivity, and raise skeletal-muscle oxidative capacity while lowering inflammatory cytokinea small immune-signaling protein, often inflammatory expression ^[2]. The unavoidable caveats are that all of this is preclinical, that the compound has no human safety data, and that its PPAR-delta agonistsomething that switches a receptor on class, including the closely related GW-501516, has been linked to tumor formation in long-term rodent studies, so it remains a research-only compound ^[3].

⚠️ A NOTE ON WHICH COMPOUND THE COLON-CANCER WARNING BELONGS TO, because it has been migrating between two molecules for twenty years. Every published result showing a PPAR-delta agonistsomething that switches a receptor on accelerating intestinal tumour growth used GW501516, sold as Cardarine ^[5]. There is no published study in which GW-0742 increased intestinal tumour burden, and there is one in which it ATTENUATED chemically induced colon carcinogenesis in mice ^[6]. The two compounds differ by a single fluorine and 18 daltons, and doping-control methods have to separate them by mass spectrometry precisely because they are otherwise so easily confused ^[4]. That does not make GW-0742 safe; it means the specific tumour finding people cite for it was generated with a different molecule, and citing it here would be the same error in the opposite direction.

Its own muscle pharmacology is real but thinner than the famous endurance headline suggests, which also belongs to GW501516. GW-0742 raised the number of oxidative fibres 1.63-fold and capillaries 1.55-fold within two days in mouse muscle, an effect that depends on calcineurin ^[7]. In primary human muscle cells from diabetic and healthy donors it increased fatty-acid oxidation in both, but did NOT restore insulinthe hormone that moves sugar out of your blood and into cells-stimulated glycogen synthesis ^[8]; those are human cells in a dish rather than dosed people. In the one endurance experiment, the large gains came from GW-0742 combined with AICAR, and no isolated GW-0742 endurance figure was reported ^[1].

It also carries at least one off-target worth naming: it antagonises the thyroid hormone receptor with an IC50 of 4.9 micromolar and blocked T3-driven vasodilationwidening of blood vessels, improving blood flow of rat arteries at 10 micromolar ^[9].

Its liver effects run in both directions depending on dose, and the entry should say both. At pharmacological doses it lowered liver enzymes and inflammatory signalling in a chemical injury model, in wild-type but not receptor-null mice ^[11]. At toxicological doses the hepatic picture reverses, through cross-activation of a different PPAR isoform.

⚠️ Two negatives are firm. No human has ever received GW-0742 in any trial; the two records that surface in a clinical-trial search gave humans telmisartan and fibrates respectively, with GW-0742 used only on cells. And no pharmacokinetic study exists in any species, so any half-lifehow long it takes for half a dose to clear your system, peak concentration or bioavailabilityhow much of a dose actually reaches your bloodstream figure circulating for this compound is unsourced.